Outlook Therapeutics names C. Russell Trenary III CEO; Lawrence Kenyon stays CFO

Outlook Therapeutics, Inc.

C. Russell Trenary III appointed President & CEO effective July 6, 2021; replaces Lawrence Kenyon who remains CFO.
Base salary $600,000; target annual cash bonus of 70% of base salary.
Received initial grant of 4,000,000 options + performance grant of 1,000,000 options with milestone vesting.
Company on track for NORSE TWO top-line data Q3 2021; plans BLA submission for ONS-5010 in Q1 2022.
Trenary previously led InnFocus through acquisition by Santen; over 35 years in life sciences.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Lawrence Kenyon

Chief Financial Officer

OTLK · Outlook Therapeutics, Inc.

Effective: 2021-07-06
Successor: C. Russell Trenary III
Filed: July 9, 2021, 7:59 PM ET

Mr. Trenary replaces Lawrence Kenyon, who resigned as President and Chief Executive Officer of the Company concurrently with Mr. Trenary’s appointment.

Appointed

C. Russell Trenary III

President and Chief Executive Officer

OTLK · Outlook Therapeutics, Inc.

Effective: 2021-07-06
Filed: July 9, 2021, 7:59 PM ET

On July 6, 2021, the Board of Directors (the “Board”) of Outlook Therapeutics, Inc. (the “Company”) appointed C. Russell Trenary III as President and Chief Executive Officer of the Company and as a director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lawrence Kenyon resigned as Chief Financial Officer at Outlook Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Mr. Trenary replaces Lawrence Kenyon, who resigned as President and Chief Executive Officer of the Company concurrently with Mr. Trenary’s appointment.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

C. Russell Trenary III was appointed as President and Chief Executive Officer at Outlook Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On July 6, 2021, the Board of Directors (the “Board”) of Outlook Therapeutics, Inc. (the “Company”) appointed C. Russell Trenary III as President and Chief Executive Officer of the Company and as a director, effective immediately.

View on SEC.gov

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-090634

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.